Price T Rowe Associates Inc. MD Boosts Holdings in Repligen Co. (NASDAQ:RGEN)

Price T Rowe Associates Inc. MD boosted its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 11.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,136,054 shares of the biotechnology company's stock after buying an additional 743,815 shares during the quarter. Price T Rowe Associates Inc. MD owned approximately 12.74% of Repligen worth $1,027,165,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. UMB Bank n.a. boosted its holdings in shares of Repligen by 49.1% in the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 110 shares during the period. Oppenheimer & Co. Inc. purchased a new stake in shares of Repligen in the 4th quarter worth $216,000. Van ECK Associates Corp grew its position in shares of Repligen by 7.8% during the 4th quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company's stock worth $6,078,000 after buying an additional 3,066 shares in the last quarter. Stephens Investment Management Group LLC increased its stake in shares of Repligen by 7.4% during the fourth quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company's stock valued at $77,267,000 after buying an additional 37,057 shares during the period. Finally, Sanctuary Advisors LLC bought a new stake in shares of Repligen in the third quarter valued at about $233,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Margaret Pax bought 250 shares of the business's stock in a transaction dated Monday, March 17th. The stock was acquired at an average price of $150.69 per share, with a total value of $37,672.50. Following the completion of the purchase, the director now directly owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 1.20% of the company's stock.

Repligen Stock Performance

Shares of NASDAQ RGEN traded down $6.38 during mid-day trading on Tuesday, hitting $137.25. The stock had a trading volume of 823,882 shares, compared to its average volume of 713,474. The company has a 50 day moving average of $139.66 and a two-hundred day moving average of $145.97. The firm has a market cap of $7.71 billion, a PE ratio of -267.99, a PEG ratio of 4.54 and a beta of 1.27. Repligen Co. has a twelve month low of $102.97 and a twelve month high of $182.52. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The firm's quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.28 EPS. Research analysts predict that Repligen Co. will post 1.72 EPS for the current fiscal year.

Wall Street Analyst Weigh In

RGEN has been the subject of several recent research reports. HC Wainwright restated a "buy" rating and issued a $180.00 price target on shares of Repligen in a report on Friday, February 21st. StockNews.com raised shares of Repligen from a "sell" rating to a "hold" rating in a research note on Monday. JPMorgan Chase & Co. increased their target price on Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. Evercore ISI initiated coverage on Repligen in a report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price target on the stock. Finally, Royal Bank of Canada upped their price objective on Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a research note on Friday, February 21st. Seven equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $176.82.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.